FDA Panel: Reformulated OxyContin Did Not Reduce Overall Abuse
An FDA advisory committee overwhelmingly panned the idea that Purdue Pharma’s abuse-deterrent formulation (ADF) of oxycodone (OxyContin) “meaningfully reduced” overall opioid abuse, overdose, and death.
Show Your Support
Access the report
Read the full report
Want to keep reading? Subscribers get exclusive access to DHI's extensive library of content, covering top-of-mind issues and trends for today's healthcare executive.